Comparing Innovation Spending: Amgen Inc. and Dr. Reddy's Laboratories Limited

Amgen vs. Dr. Reddy's: A Decade of R&D Investment

__timestampAmgen Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014429700000012402000000
Thursday, January 1, 2015407000000017449000000
Friday, January 1, 2016384000000017834000000
Sunday, January 1, 2017356200000019551000000
Monday, January 1, 2018373700000018265000000
Tuesday, January 1, 2019411600000015607000000
Wednesday, January 1, 2020420700000015410000000
Friday, January 1, 2021481900000016541000000
Saturday, January 1, 2022443400000017482000000
Sunday, January 1, 2023478400000019381000000
Monday, January 1, 2024596400000022873000000
Loading chart...

Infusing magic into the data realm

Innovation Spending: A Tale of Two Giants

In the ever-evolving pharmaceutical landscape, innovation is the lifeblood that fuels growth and competitiveness. Amgen Inc. and Dr. Reddy's Laboratories Limited, two titans in the industry, have demonstrated contrasting approaches to research and development (R&D) spending over the past decade. From 2014 to 2023, Amgen's R&D expenses have shown a steady increase, peaking in 2021 with a 35% rise from 2017. Meanwhile, Dr. Reddy's Laboratories has consistently outpaced Amgen, with R&D spending nearly doubling from 2014 to 2023. This strategic investment underscores Dr. Reddy's commitment to innovation, despite a slight dip in 2019 and 2020. The data reveals a fascinating narrative of how these companies prioritize innovation, with Dr. Reddy's leading the charge in recent years. As we look to the future, the missing data for Amgen in 2024 leaves us curious about their next strategic move.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025